Turning the Page on Zohydro? New Formulations, New Division Leadership Should Help FDA Move Forward in Opioids
This article was originally published in RPM Report
The long-time head of FDA’s pain drug review group, Bob Rappaport, has retired after 20 years at FDA. The new acting Division Director is Sharon Hertz – suggesting continuity in the substance of reviews, but perhaps a symbolic change in moving beyond the controversy over Zohydro.